Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.645 +0.025 (+0.44%)
Streaming Delayed Price Updated: 11:58 AM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MannKind Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
News headline image
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
From MannKind
Via GlobeNewswire
News headline image
MannKind (MNKD) Q3 2024 Earnings Call Transcript ↗
MNKD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at 2024 UBS Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
From MannKind
Via GlobeNewswire
News headline image
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham... 
Via Newsfile
News headline image
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
From MannKind
Via GlobeNewswire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
MannKind to Present at Upcoming Conferences
From MannKind
Via GlobeNewswire
News headline image
Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board
From MannKind
Via GlobeNewswire
News headline image
MannKind (MNKD) Q2 2024 Earnings Call Transcript ↗
MNKD earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 9:00 a.m. (ET) 
From MannKind
Via GlobeNewswire
News headline image
MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024
From MannKind
Via GlobeNewswire
News headline image
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker ↗
Our first-ever twin bill. 
Via The Motley Fool
News headline image
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
News headline image
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
From MannKind
Via GlobeNewswire
News headline image
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
From MannKind
Via GlobeNewswire
News headline image
MannKind (MNKD) Q1 2024 Earnings Call Transcript ↗
MNKD earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
MNKD Stock Earnings: MannKind Beats EPS, Beats Revenue for Q1 2024 ↗
MNKD stock results show that MannKind beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
News headline image
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
From MannKind
Via GlobeNewswire
News headline image
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease
From MannKind
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.